Myalgic Encephalomyelitis
36
4
5
20
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.3%
3 terminated out of 36 trials
87.0%
+0.5% vs benchmark
6%
2 trials in Phase 3/4
10%
2 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (36)
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Cardiovascular Analysis of PEM
A 3-day Course for CFS/ME
Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Long-term Sequelae of COVID-19 (Myalgic Encephalomyelitis): An International Cross-Sectional Study
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in ME/CFS
The Long COVID-19 Wearable Device Study
A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS
Effect of Stellate Ganglion Block on ME/CFS
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
The Comeback Study
Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS
Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors
Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients